The 17th Shanghai Breast Cancer Professional Symposium 丨Professor Benlong Yang: Exercising Caution in Surgical Indications for Advanced Breast Cancer and Strictly Upholding the Threshold for Prophylactic Mastectomy

The 17th Shanghai Breast Cancer Professional Symposium 丨Professor Benlong Yang: Exercising Caution in Surgical Indications for Advanced Breast Cancer and Strictly Upholding the Threshold for Prophylactic Mastectomy

Recently, the 17th Shanghai Breast Cancer Professional Symposium, held in conjunction with the Annual Meeting of the Breast Cancer Committee of the Shanghai Anti-Cancer Association and the 2026 Breast Cancer Guideline “Red Book” Update Meeting, took place in Shanghai. During the meeting, the 2026 Edition of the Essentials of the Breast Cancer Diagnosis and Treatment Guidelines and Specifications—jointly issued by the Chinese Anti-Cancer Association Breast Cancer Committee (CBCS) and the Breast Oncology Group of the Chinese Society of Clinical Oncology (CSOBO)—was officially released (hereinafter referred to as the new Red Book).
SABCS Expert Commentary | Professor Jin Feng: Reanalysis of the Landmark NSABP B-20 Trial—Can MMAI Become a Low-Cost Option for Risk Stratification?

SABCS Expert Commentary | Professor Jin Feng: Reanalysis of the Landmark NSABP B-20 Trial—Can MMAI Become a Low-Cost Option for Risk Stratification?

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a reanalysis of the landmark NSABP B-20 trial (Abstract No. RF3-03) was presented, exploring the prognostic value and chemotherapy benefit–predictive potential of a multimodal artificial intelligence (MMAI) model based on digital pathology and clinical data in hormone receptor–positive (HR+), node-negative early breast cancer.
SABCS Expert Commentary |Professor Jin Feng: New Evidence for Precision Immunotherapy in Early Triple-Negative Breast Cancer—Gene Expression Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

SABCS Expert Commentary |Professor Jin Feng: New Evidence for Precision Immunotherapy in Early Triple-Negative Breast Cancer—Gene Expression Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study titled “Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. The study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early triple-negative breast cancer (TNBC), revealing the predictive value of tumor-infiltrating lymphocytes (TILs) and molecular TNBC subtypes for treatment efficacy.
SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies

De-escalation therapy has become an important trend in the management of HER2-positive early breast cancer, yet accurately identifying patients who can safely omit chemotherapy remains a major challenge. At the 2025 San Antonio Breast Cancer Symposium (SABCS), the PHERGuide substudy innovatively incorporated circulating tumor DNA (ctDNA) monitoring into the neoadjuvant treatment framework. The study demonstrated that ctDNA clearance is strongly associated with pathological complete response (pCR), while baseline ctDNA positivity predicts poorer outcomes.